Vancouver, British Columbia — November 18, 2025 — Leads & Copy — Zymeworks Inc. (Nasdaq: ZYME) has appointed Scott Platshon as Acting Chief Investment Officer, effective immediately. Platshon will manage future cash flows from Ziihera® and the company’s healthcare asset aggregation strategy.
In his new part-time role, Platshon will report to Zymeworks Chair and CEO Kenneth Galbraith. He will work to manage expected future cash flows from Ziihera® (zanidatamab-hrii) and other licensed product candidates such as pasritamig, currently in Phase 3 registration studies by Johnson & Johnson Innovative Medicine.
Platshon will also oversee the operational execution of Zymeworks’ healthcare asset aggregation strategy.
Concurrent with the appointment, Platshon stepped down from Zymeworks’ Board of Directors, where he has served since February 2024.
Galbraith said the appointment strategically positions Zymeworks to drive long-term returns by building a diversified portfolio of revenue-generating assets, following positive topline data from the Phase 3 HERIZON-GEA-01 trial evaluating zanidatamab in combination with chemotherapy with or without the PD-1 inhibitor Tevimbra® (tislelizumab).
Galbraith noted that Platshon has been working with him and the Board to complement their active R&D operations with a strategic initiative to generate attractive long-term shareholder returns from an integrated business approach.
Platshon has worked at EcoR1 Capital, LLC, a biotech-focused investment fund, since 2015 and as a Partner since 2020. He will continue his role at EcoR1 Capital, LLC.
Prior to joining EcoR1 Capital, LLC, he was an analyst at Aquilo Partners, a San Francisco-based life sciences investment bank. Platshon also serves on the board of directors of Kumquat Biosciences and Ajax Therapeutics. He holds a B.S. in Bioengineering from Stanford University.
Platshon said he shares Zymeworks’ strategic vision to pursue innovation and growth and sees opportunity to leverage its cash flows to build a disciplined, high-return portfolio that creates sustainable value creation over the long-term.
Zymeworks is managing a portfolio of licensed healthcare assets, while developing a pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease.
In addition to Ziihera® (zanidatamab-hrii), its asset and royalty aggregation strategy focuses on optimizing positive future cash flows from pasritamig, and other licensed products and product candidates. Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the early-stage development of innovative medicines.
Zymeworks has separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. The company’s expertise in antibody drug conjugates and multispecific antibody therapeutics target novel pathways in areas of significant unmet medical need.
Zymeworks’ complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been leveraged through strategic partnerships with global biopharmaceutical companies.
Contact:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Source: Zymeworks Inc.
